SCHEMBL4655922

SCHEMBL4655922

C=CCc1ccc(CC(=O)OC)cc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
GAA P10253 2/20 0.54
GFER P55789 1/20 0.54
HSP90AB1 P08238 1/20 0.46
ALOX5 P09917 2/20 0.44
PTGS1 P23219 2/20 0.44
CYP3A4 P08684 1/20 0.44
AR P10275 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
XDH P47989 1/20 0.44
TLR7 Q9NYK1 3/20 0.43
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
CNR2 P34972 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
PDK2 Q15119 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7041553 0.88 ALDH1A1 (0.57) ALDH1A1GAAGFERHSP90AB1ALOX5
SCHEMBL3267701 0.86 MAPK1 (0.47) ALDH1A1ALOX5PTGS1CYP3A4AR
SCHEMBL8146212 0.84 GAA (0.63) ALDH1A1GAAGFERHSP90AB1CYP4F2
SCHEMBL20766302 0.81 GAA (0.55) ALDH1A1GAAGFERHSP90AB1CYP4F2
SCHEMBL7042257 0.80 HSP90AB1 (0.54) ALDH1A1GAAGFERHSP90AB1ALOX5
SCHEMBL7041490 0.78 PTGDR (0.44) ALDH1A1GAAGFERALOX5PTGS1
SCHEMBL15499988 0.78 GAA (0.55) ALDH1A1GAAGFERHSP90AB1CYP4F2
SCHEMBL29446278 0.77 GAA (0.72) ALDH1A1GAAGFERHSP90AB1PTGS1
SCHEMBL3668882 0.77 GAA (0.72) ALDH1A1GAAGFERHSP90AB1PTGS1
SCHEMBL1006107 0.77 XDH (0.70) ALDH1A1GAAALOX5PTGS1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996198-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR Kalypsys, Inc. (US) 2008-12-03 EP disclosed
WO-2007109577-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2007-09-27 WO disclosed
WO-2007109577-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2007-09-27 WO disclosed
US-20070219193-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR KALYPSYS, INC (US) 2007-09-20 US disclosed
US-20070219193-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR KALYPSYS, INC (US) 2007-09-20 US disclosed
US-20070219193-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR KALYPSYS, INC (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219193-A1 ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR PPARG, PPARA, PPARD ALDH1A1 882/4885GAA 1471/4885GFER 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.